Creative Medical Technology Holdings, INC 10-K annual reports

Creative Medical Technology Holdings files an amendment to its 2025 Annual Report, detailing executive compensation, governance, and related-party transactions.

Creative Medical Technology Holdings, Inc. reported increased net losses for 2025 despite significant clinical trial advancements and successful capital raises, highlighting ongoing R&D investment.

Creative Medical Technology Holdings files an amendment to its 2024 annual report, providing updates on executive compensation, director information, related party transactions, and other corporate governance matters.

Creative Medical Technology Holdings files an amendment to its annual report to include a clawback policy in compliance with Nasdaq listing rules.

Creative Medical Technology Holdings files an amendment to its annual report to correct the number of outstanding shares and the date of the independent auditor's report.

Creative Medical Technology Holdings reports its financial results for the year ended December 31, 2024, and provides updates on its clinical programs and pipeline development.

Creative Medical Technology Holdings has filed an amended 10-K report detailing executive compensation, related party transactions, and director information for the fiscal year ended December 31, 2023.

Creative Medical Technology Holdings reported its full year 2023 results, highlighting progress in clinical trials and platform development, while also noting a decrease in revenue from its commercial products.